Remdesivir for the Treatment of COVID-19 in the Inpatient Setting

08 / 151 Remdesivir for the Treatment of COVID-19 in the Inpatient Setting Introduction and Rationale Objectives The objective is to evaluate the efficacy and safety of remdesivir for the treatment of COVID-19 in hospitalized adults and adolescents (inpatients). [...] The first part of the form involves describing what was reported to have happened in the study; the second part involves assigning a judgment relating to the ROB for that entry by answering a prespecified question about the adequacy of the study in relation to the entry, including a judgment of low, high, or unclear ROB. [...] The mean age of patients in the remdesivir group was 65 years (IQR, 53 years to 77 years) and 66 years (IQR, 54 years to 77 years) 26 / 151 Remdesivir for the Treatment of COVID-19 in the Inpatient Setting Results of Clinical Evaluation in the SoC group; overall, 40.2% were female and 59.8% were male. [...] The results showed patients in the remdesivir group had a statistically significantly shorter time to improvement of 1 category 35 / 151 Remdesivir for the Treatment of COVID-19 in the Inpatient Setting Results of Clinical Evaluation (HR = 1.23; 95% CI, 1.08 to 1.41) or 2 categories (HR = 1.29; 95% CI, 1.12 to 1.48) on the ordinal scale from baseline than patients in the placebo group, and a short. [...] Time to modified recovery (improvement from a baseline NC score of 2 to 4 to a score of 5 to 7; improvement from a baseline score of 5 to a score of 6 to 7; or improvement from a baseline score of 6 to a score of 7) in days, within 28 daysd 10-day remdesivir (n = 193): 7 (4 to 12) 5-day remdesivir (n = 191): 6 (4 to 9) SoC (n = 200): 7 (4 to 14) 10-day vs.